Citi analyst Yigal Nochomovitz opened a "Upside 90-Day Catalyst Watch" on shares of Rain Oncology while keeping a Buy rating on the shares with a $29 price target. Topline results from the Phase 3 MANTRA study evaluating milademetan in dedifferentiated liposarcoma are expected in Q1, the analyst tells investors in a research note. Citi believes the shares could trade up as much as 100% if the MANTRA progression free survival results are meaningfully better than the bar set by Halaven and Yondelis at 2.0-2.2 months.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAIN:
- Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
- Rain Oncology announces publication of Phase 1 data of milademetan
- Rain Oncology initiated with a Buy at Mizuho
- Rain Oncology initiated with a Buy at EF Hutton
- Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.
